Live Breaking News & Updates on Myesha Lacy Adverum Biotechnologies Inc

Stay updated with breaking news from Myesha lacy adverum biotechnologies inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors

Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
REDWOOD CITY, Calif., Dec. 14, 2020 Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum’s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co.
“Dawn is a highly-esteemed industry veteran who brings extensive global commercial leadership experience to the board,” said Laurent Fischer, M.D., chief executive officer of Adverum Biotechnologies. “We have begun to build pre-commercial capabilities as we aim to advance ADVM-022 toward our first Pha ....

United States , Laurent Fischer , Asia Pacific , Adverum Biotechnologies Inc , Myesha Lacy Adverum Biotechnologies Inc , Merck Co , Global Blood Therapeutics Inc , Xenon Pharmaceuticals , Theratechnologies Inc , Carleton University , Adverum Biotechnologies , Dawn Svoronos , Merck Canada , Global Blood Therapeutics , Private Securities Litigation Reform Act , Media Inquiries , Myesha Lacy , ஒன்றுபட்டது மாநிலங்களில் , பரிசு பெற்றவர் பிஷ்ஷர் , ஆசியா பெஸிஃபிக் , மெர்க் இணை , உலகளாவிய இரத்தம் சிகிச்சை இன்க் , ஐயீநாந் மருந்துகள் , கார்லேடன் பல்கலைக்கழகம் , மெர்க் கனடா , உலகளாவிய இரத்தம் சிகிச்சை ,

Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors

Share:
REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co.
Dawn is a highly-esteemed industry veteran who brings extensive global commercial leadership experience to the board, said Laurent Fischer, M.D., chief executive officer of Adverum Biotechnologies. We have begun to build pre-commercial capabilities as we aim to advance ADVM-022 toward our first Phase 2b pivotal trial in mid-2021. Since ADVM-022 is in development for two large ocular disease indications, wet AMD and DME, it is critical to be prepared for global commercialization. Dawn ....

United States , Laurent Fischer , Asia Pacific , Adverum Biotechnologies Inc , Myesha Lacy Adverum Biotechnologies Inc , Merck Co , Global Blood Therapeutics Inc , Xenon Pharmaceuticals , Theratechnologies Inc , Carleton University , Dawn Svoronos , Merck Canada , Global Blood Therapeutics , Private Securities Litigation Reform Act , Media Inquiries , Myesha Lacy Adverum Biotechnologies , ஒன்றுபட்டது மாநிலங்களில் , பரிசு பெற்றவர் பிஷ்ஷர் , ஆசியா பெஸிஃபிக் , மெர்க் இணை , உலகளாவிய இரத்தம் சிகிச்சை இன்க் , ஐயீநாந் மருந்துகள் , கார்லேடன் பல்கலைக்கழகம் , மெர்க் கனடா , உலகளாவிய இரத்தம் சிகிச்சை , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,